Malignant Melanoma Recruiting Phase 2 Trials for Cobimetinib (DB05239)

Also known as: Melanoma, Malignant / [M]Malignant melanoma NOS (morphologic abnormality) / Melanoma / Malignant melanoma (morphologic abnormality) / Malignant melanoma (disorder) / [M]Malignant melanoma NOS or melanocarcinoma or melanoma NOS / Melanoma: [skin] or [malignant] / Melanoma malignant

IndicationStatusPhase
DBCOND0029825 (Malignant Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02303951Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTreatment